Comparative Pharmacology
Head-to-head clinical analysis: KOROSTATIN versus MEVACOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KOROSTATIN versus MEVACOR.
KOROSTATIN vs MEVACOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KOROSTATIN is a direct thrombin inhibitor that binds reversibly to the active site of thrombin, blocking its interaction with substrates and thereby inhibiting fibrin formation, platelet activation, and coagulation cascade amplification.
Competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. Reduces hepatic cholesterol synthesis, leading to increased LDL receptor expression and enhanced clearance of LDL from plasma.
50 mg orally twice daily
10-80 mg orally once daily in the evening.
None Documented
None Documented
8-12 hours in normal renal function; prolonged to 24-36 hours in severe renal impairment (CrCl <30 mL/min)
The terminal elimination half-life of lovastatin is approximately 1-2 hours for the parent drug. However, the active metabolite (lovastatin acid) has a half-life of about 1.7-2.6 hours. Despite the short half-life, the duration of HMG-CoA reductase inhibition is prolonged due to enterohepatic recirculation and tissue distribution. Once-daily dosing is effective for LDL-C reduction.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Lovastatin is primarily excreted via the biliary/fecal route (approximately 80-85% of the absorbed dose) as metabolites. Renal excretion accounts for about 10% of the administered dose, mostly as metabolites; less than 5% is excreted unchanged in urine.
Category C
Category C
HMG-CoA Reductase Inhibitor (Statin)
HMG-CoA Reductase Inhibitor (Statin)